#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=The objective of this paper was using the Essential Medicines List for children by the World Health Organization ( WHO ) to create a provisional pediatric biopharmaceutics classification system ( pBCS ) for oral drugs and to compare our results with the BCS for adults ( aBCS ) .
2-1	16-19	The	abstract[2]	new[2]	_	_
2-2	20-29	objective	abstract[2]	new[2]	_	_
2-3	30-32	of	abstract[2]	new[2]	_	_
2-4	33-37	this	abstract[2]|object[3]	new[2]|new[3]	_	_
2-5	38-43	paper	abstract[2]|object[3]	new[2]|new[3]	_	_
2-6	44-47	was	_	_	_	_
2-7	48-53	using	_	_	_	_
2-8	54-57	the	object[5]	new[5]	coref	3-8[19_5]
2-9	58-67	Essential	object[5]	new[5]	_	_
2-10	68-77	Medicines	quantity|object[5]	new|new[5]	coref	3-13[20_0]
2-11	78-82	List	object[5]	new[5]	_	_
2-12	83-86	for	object[5]	new[5]	_	_
2-13	87-95	children	object[5]|person[6]	new[5]|new[6]	coref	3-16[0_6]
2-14	96-98	by	object[5]|person[6]	new[5]|new[6]	_	_
2-15	99-102	the	object[5]|person[6]|organization[7]	new[5]|new[6]|new[7]	_	_
2-16	103-108	World	object[5]|person[6]|organization[7]	new[5]|new[6]|new[7]	_	_
2-17	109-115	Health	object[5]|person[6]|organization[7]	new[5]|new[6]|new[7]	_	_
2-18	116-128	Organization	object[5]|person[6]|organization[7]	new[5]|new[6]|new[7]	_	_
2-19	129-130	(	_	_	_	_
2-20	131-134	WHO	_	_	_	_
2-21	135-136	)	_	_	_	_
2-22	137-139	to	_	_	_	_
2-23	140-146	create	_	_	_	_
2-24	147-148	a	abstract[10]	new[10]	appos	2-31[0_10]
2-25	149-160	provisional	abstract[10]	new[10]	_	_
2-26	161-170	pediatric	abstract[10]	new[10]	_	_
2-27	171-187	biopharmaceutics	abstract|abstract[10]	new|new[10]	_	_
2-28	188-202	classification	abstract|abstract[10]	new|new[10]	_	_
2-29	203-209	system	abstract[10]	new[10]	_	_
2-30	210-211	(	_	_	_	_
2-31	212-216	pBCS	abstract	giv	coref	3-23[24_0]
2-32	217-218	)	_	_	_	_
2-33	219-222	for	_	_	_	_
2-34	223-227	oral	substance[12]	new[12]	coref	4-5[27_12]
2-35	228-233	drugs	substance[12]	new[12]	_	_
2-36	234-237	and	_	_	_	_
2-37	238-240	to	_	_	_	_
2-38	241-248	compare	_	_	_	_
2-39	249-252	our	person|abstract[14]	acc|new[14]	_	_
2-40	253-260	results	abstract[14]	new[14]	_	_
2-41	261-265	with	abstract[14]	new[14]	_	_
2-42	266-269	the	abstract[14]|abstract[15]	new[14]|new[15]	_	_
2-43	270-273	BCS	abstract[14]|abstract[15]	new[14]|new[15]	_	_
2-44	274-277	for	abstract[14]|abstract[15]	new[14]|new[15]	_	_
2-45	278-284	adults	abstract[14]|abstract[15]|person	new[14]|new[15]|new	coref	8-17
2-46	285-286	(	_	_	_	_
2-47	287-291	aBCS	abstract	new	_	_
2-48	292-293	)	_	_	_	_
2-49	294-295	.	_	_	_	_

#Text=Since 2007 , the WHO has provided the WHO Model List of Essential Medicines for Children ; a core drug list for a basic health-care system .
3-1	296-301	Since	_	_	_	_
3-2	302-306	2007	time	new	_	_
3-3	307-308	,	_	_	_	_
3-4	309-312	the	_	_	_	_
3-5	313-316	WHO	_	_	_	_
3-6	317-320	has	_	_	_	_
3-7	321-329	provided	_	_	_	_
3-8	330-333	the	object[19]	giv[19]	_	_
3-9	334-337	WHO	object[19]	giv[19]	_	_
3-10	338-343	Model	object[19]	giv[19]	_	_
3-11	344-348	List	object[19]	giv[19]	_	_
3-12	349-351	of	object[19]	giv[19]	_	_
3-13	352-361	Essential	object[19]|quantity[20]	giv[19]|giv[20]	_	_
3-14	362-371	Medicines	object[19]|quantity[20]	giv[19]|giv[20]	_	_
3-15	372-375	for	object[19]|quantity[20]	giv[19]|giv[20]	_	_
3-16	376-384	Children	object[19]|quantity[20]|person	giv[19]|giv[20]|giv	coref	21-1
3-17	385-386	;	_	_	_	_
3-18	387-388	a	object[23]	new[23]	coref	4-1[26_23]
3-19	389-393	core	object[23]	new[23]	_	_
3-20	394-398	drug	substance|object[23]	new|new[23]	coref	9-14
3-21	399-403	list	object[23]	new[23]	_	_
3-22	404-407	for	object[23]	new[23]	_	_
3-23	408-409	a	object[23]|abstract[24]	new[23]|giv[24]	_	_
3-24	410-415	basic	object[23]|abstract[24]	new[23]|giv[24]	_	_
3-25	416-427	health-care	object[23]|abstract[24]	new[23]|giv[24]	_	_
3-26	428-434	system	object[23]|abstract[24]	new[23]|giv[24]	_	_
3-27	435-436	.	_	_	_	_

#Text=This resource list considers the safest , efficacious and cost-effective drugs for priority pathologies in pediatrics up to 12 years old .
4-1	437-441	This	object[26]	giv[26]	coref	5-11[34_26]
4-2	442-450	resource	abstract|object[26]	new|giv[26]	_	_
4-3	451-455	list	object[26]	giv[26]	_	_
4-4	456-465	considers	_	_	_	_
4-5	466-469	the	substance[27]	giv[27]	coref	5-4[32_27]
4-6	470-476	safest	substance[27]	giv[27]	_	_
4-7	477-478	,	substance[27]	giv[27]	_	_
4-8	479-490	efficacious	substance[27]	giv[27]	_	_
4-9	491-494	and	substance[27]	giv[27]	_	_
4-10	495-509	cost-effective	substance[27]	giv[27]	_	_
4-11	510-515	drugs	substance[27]	giv[27]	_	_
4-12	516-519	for	substance[27]	giv[27]	_	_
4-13	520-528	priority	substance[27]|abstract[28]	giv[27]|new[28]	_	_
4-14	529-540	pathologies	substance[27]|abstract[28]	giv[27]|new[28]	_	_
4-15	541-543	in	substance[27]|abstract[28]	giv[27]|new[28]	_	_
4-16	544-554	pediatrics	substance[27]|abstract[28]|person[29]	giv[27]|new[28]|new[29]	coref	9-2[51_29]
4-17	555-557	up	substance[27]|abstract[28]|person[29]	giv[27]|new[28]|new[29]	_	_
4-18	558-560	to	_	_	_	_
4-19	561-563	12	time[30]	new[30]	_	_
4-20	564-569	years	time[30]	new[30]	_	_
4-21	570-573	old	_	_	_	_
4-22	574-575	.	_	_	_	_

#Text=All immediate release oral drugs from the sixth edition of this list were selected for this work .
5-1	576-579	All	event[31]	new[31]	_	_
5-2	580-589	immediate	event[31]	new[31]	_	_
5-3	590-597	release	event[31]	new[31]	_	_
5-4	598-602	oral	substance[32]	giv[32]	coref	8-23[47_32]
5-5	603-608	drugs	substance[32]	giv[32]	_	_
5-6	609-613	from	substance[32]	giv[32]	_	_
5-7	614-617	the	substance[32]|abstract[33]	giv[32]|new[33]	_	_
5-8	618-623	sixth	substance[32]|abstract[33]	giv[32]|new[33]	_	_
5-9	624-631	edition	substance[32]|abstract[33]	giv[32]|new[33]	_	_
5-10	632-634	of	substance[32]|abstract[33]	giv[32]|new[33]	_	_
5-11	635-639	this	substance[32]|abstract[33]|object[34]	giv[32]|new[33]|giv[34]	_	_
5-12	640-644	list	substance[32]|abstract[33]|object[34]	giv[32]|new[33]|giv[34]	_	_
5-13	645-649	were	_	_	_	_
5-14	650-658	selected	_	_	_	_
5-15	659-662	for	_	_	_	_
5-16	663-667	this	abstract[35]	new[35]	_	_
5-17	668-672	work	abstract[35]	new[35]	_	_
5-18	673-674	.	_	_	_	_

#Text=The need for and importance of developing appropriate , safe and effective medicines for pediatrics have now been recognized .
6-1	675-678	The	abstract[36]	new[36]	coref	24-1[166_36]
6-2	679-683	need	abstract[36]	new[36]	_	_
6-3	684-687	for	_	_	_	_
6-4	688-691	and	_	_	_	_
6-5	692-702	importance	abstract	new	_	_
6-6	703-705	of	_	_	_	_
6-7	706-716	developing	_	_	_	_
6-8	717-728	appropriate	abstract[38]	new[38]	coref	24-5[167_38]
6-9	729-730	,	abstract[38]	new[38]	_	_
6-10	731-735	safe	abstract[38]	new[38]	_	_
6-11	736-739	and	abstract[38]	new[38]	_	_
6-12	740-749	effective	abstract[38]	new[38]	_	_
6-13	750-759	medicines	abstract[38]	new[38]	_	_
6-14	760-763	for	abstract[38]	new[38]	_	_
6-15	764-774	pediatrics	abstract[38]|abstract	new[38]|new	_	_
6-16	775-779	have	_	_	_	_
6-17	780-783	now	_	_	_	_
6-18	784-788	been	_	_	_	_
6-19	789-799	recognized	_	_	_	_
6-20	800-801	.	_	_	_	_

#Text=Pediatrics have long been considered as a therapeutically disregarded group .
7-1	802-812	Pediatrics	abstract	new	coref	20-14[146_0]
7-2	813-817	have	_	_	_	_
7-3	818-822	long	_	_	_	_
7-4	823-827	been	_	_	_	_
7-5	828-838	considered	_	_	_	_
7-6	839-841	as	_	_	_	_
7-7	842-843	a	_	_	_	_
7-8	844-859	therapeutically	_	_	_	_
7-9	860-871	disregarded	_	_	_	_
7-10	872-877	group	_	_	_	_
7-11	878-879	.	_	_	_	_

#Text=This fact lies in the therapeutic gap that originates from formulation development ( mainly focused on adults ) , low availability of commercial pediatric drugs for pediatric use and physiological and anatomical differences relative to the adult population .
8-1	880-884	This	abstract[41]	new[41]	_	_
8-2	885-889	fact	abstract[41]	new[41]	_	_
8-3	890-894	lies	_	_	_	_
8-4	895-897	in	_	_	_	_
8-5	898-901	the	abstract[42]	new[42]	_	_
8-6	902-913	therapeutic	abstract[42]	new[42]	_	_
8-7	914-917	gap	abstract[42]	new[42]	_	_
8-8	918-922	that	_	_	_	_
8-9	923-933	originates	_	_	_	_
8-10	934-938	from	_	_	_	_
8-11	939-950	formulation	abstract|abstract[44]	new|new[44]	coref	25-47[180_0]
8-12	951-962	development	abstract[44]	new[44]	_	_
8-13	963-964	(	_	_	_	_
8-14	965-971	mainly	_	_	_	_
8-15	972-979	focused	_	_	_	_
8-16	980-982	on	_	_	_	_
8-17	983-989	adults	person	giv	coref	9-22
8-18	990-991	)	_	_	_	_
8-19	992-993	,	_	_	_	_
8-20	994-997	low	abstract[46]	new[46]	_	_
8-21	998-1010	availability	abstract[46]	new[46]	_	_
8-22	1011-1013	of	abstract[46]	new[46]	_	_
8-23	1014-1024	commercial	abstract[46]|substance[47]	new[46]|giv[47]	coref	10-31[0_47]
8-24	1025-1034	pediatric	abstract[46]|substance[47]	new[46]|giv[47]	_	_
8-25	1035-1040	drugs	abstract[46]|substance[47]	new[46]|giv[47]	_	_
8-26	1041-1044	for	abstract[46]|substance[47]	new[46]|giv[47]	_	_
8-27	1045-1054	pediatric	abstract[46]|substance[47]|abstract[48]	new[46]|giv[47]|new[48]	_	_
8-28	1055-1058	use	abstract[46]|substance[47]|abstract[48]	new[46]|giv[47]|new[48]	_	_
8-29	1059-1062	and	abstract[46]|substance[47]	new[46]|giv[47]	_	_
8-30	1063-1076	physiological	abstract[46]|substance[47]|abstract[49]	new[46]|giv[47]|new[49]	coref	10-1[58_49]
8-31	1077-1080	and	abstract[46]|substance[47]|abstract[49]	new[46]|giv[47]|new[49]	_	_
8-32	1081-1091	anatomical	abstract[46]|substance[47]|abstract[49]	new[46]|giv[47]|new[49]	_	_
8-33	1092-1103	differences	abstract[46]|substance[47]|abstract[49]	new[46]|giv[47]|new[49]	_	_
8-34	1104-1112	relative	abstract[46]|substance[47]|abstract[49]	new[46]|giv[47]|new[49]	_	_
8-35	1113-1115	to	_	_	_	_
8-36	1116-1119	the	person[50]	new[50]	_	_
8-37	1120-1125	adult	person[50]	new[50]	_	_
8-38	1126-1136	population	person[50]	new[50]	_	_
8-39	1137-1138	.	_	_	_	_

#Text=In younger pediatrics , neonates and infants , the therapeutic-risk benefits associated with drug treatment may be different from those in adults .
9-1	1139-1141	In	_	_	_	_
9-2	1142-1149	younger	person[51]	giv[51]	_	_
9-3	1150-1160	pediatrics	person[51]	giv[51]	_	_
9-4	1161-1162	,	_	_	_	_
9-5	1163-1171	neonates	person	new	coref	17-6
9-6	1172-1175	and	_	_	_	_
9-7	1176-1183	infants	person	new	_	_
9-8	1184-1185	,	_	_	_	_
9-9	1186-1189	the	abstract[54]	new[54]	_	_
9-10	1190-1206	therapeutic-risk	abstract[54]	new[54]	_	_
9-11	1207-1215	benefits	abstract[54]	new[54]	_	_
9-12	1216-1226	associated	_	_	_	_
9-13	1227-1231	with	_	_	_	_
9-14	1232-1236	drug	substance|abstract[56]	giv|new[56]	coref	10-18
9-15	1237-1246	treatment	abstract[56]	new[56]	_	_
9-16	1247-1250	may	_	_	_	_
9-17	1251-1253	be	_	_	_	_
9-18	1254-1263	different	_	_	_	_
9-19	1264-1268	from	_	_	_	_
9-20	1269-1274	those	_	_	_	_
9-21	1275-1277	in	_	_	_	_
9-22	1278-1284	adults	person	giv	coref	14-16[102_0]
9-23	1285-1286	.	_	_	_	_

#Text=Developmental physiological differences ( as the composition of gastrointestinal fluids and the presence or activity of intestinal drug metabolizing enzymes and efflux transporters ) can markedly alter the bioavailability of drugs .
10-1	1287-1300	Developmental	abstract[58]	giv[58]	coref	19-5[137_58]
10-2	1301-1314	physiological	abstract[58]	giv[58]	_	_
10-3	1315-1326	differences	abstract[58]	giv[58]	_	_
10-4	1327-1328	(	abstract[58]	giv[58]	_	_
10-5	1329-1331	as	abstract[58]	giv[58]	_	_
10-6	1332-1335	the	abstract[58]	giv[58]	_	_
10-7	1336-1347	composition	abstract[58]	giv[58]	_	_
10-8	1348-1350	of	abstract[58]	giv[58]	_	_
10-9	1351-1367	gastrointestinal	abstract[58]|substance[59]	giv[58]|new[59]	coref	11-7[72_59]
10-10	1368-1374	fluids	abstract[58]|substance[59]	giv[58]|new[59]	_	_
10-11	1375-1378	and	abstract[58]	giv[58]	_	_
10-12	1379-1382	the	abstract[58]|abstract[60]	giv[58]|new[60]	_	_
10-13	1383-1391	presence	abstract[58]|abstract[60]	giv[58]|new[60]	_	_
10-14	1392-1394	or	abstract[58]	giv[58]	_	_
10-15	1395-1403	activity	abstract[58]|abstract	giv[58]|new	coref	16-10
10-16	1404-1406	of	abstract[58]	giv[58]	_	_
10-17	1407-1417	intestinal	abstract[58]|substance[64]|abstract[65]	giv[58]|new[64]|new[65]	coref|coref	15-17[111_64]|15-17[112_65]
10-18	1418-1422	drug	abstract[58]|substance|substance[64]|abstract[65]	giv[58]|giv|new[64]|new[65]	coref	11-17
10-19	1423-1435	metabolizing	abstract[58]|abstract|substance[64]|abstract[65]	giv[58]|new|new[64]|new[65]	coref	15-18
10-20	1436-1443	enzymes	abstract[58]|substance[64]|abstract[65]	giv[58]|new[64]|new[65]	_	_
10-21	1444-1447	and	abstract[58]|abstract[65]	giv[58]|new[65]	_	_
10-22	1448-1454	efflux	abstract[58]|abstract[65]|abstract|person[67]	giv[58]|new[65]|new|new[67]	coref|coref	15-21[0_67]|19-15
10-23	1455-1467	transporters	abstract[58]|abstract[65]|person[67]	giv[58]|new[65]|new[67]	_	_
10-24	1468-1469	)	abstract[58]	giv[58]	_	_
10-25	1470-1473	can	_	_	_	_
10-26	1474-1482	markedly	_	_	_	_
10-27	1483-1488	alter	_	_	_	_
10-28	1489-1492	the	abstract[68]	new[68]	coref	15-9[0_68]
10-29	1493-1508	bioavailability	abstract[68]	new[68]	_	_
10-30	1509-1511	of	abstract[68]	new[68]	_	_
10-31	1512-1517	drugs	abstract[68]|substance	new[68]|giv	coref	12-7[82_0]
10-32	1518-1519	.	_	_	_	_

#Text=Age-related changes in the characteristics of luminal fluids such as pH may lead to changes in drug solubility and , therefore , in absorption since only the dissolved drug would be available for absorption .
11-1	1520-1531	Age-related	abstract[70]	new[70]	_	_
11-2	1532-1539	changes	abstract[70]	new[70]	_	_
11-3	1540-1542	in	abstract[70]	new[70]	_	_
11-4	1543-1546	the	abstract[70]|abstract[71]	new[70]|new[71]	_	_
11-5	1547-1562	characteristics	abstract[70]|abstract[71]	new[70]|new[71]	_	_
11-6	1563-1565	of	abstract[70]|abstract[71]	new[70]|new[71]	_	_
11-7	1566-1573	luminal	abstract[70]|abstract[71]|substance[72]	new[70]|new[71]|giv[72]	_	_
11-8	1574-1580	fluids	abstract[70]|abstract[71]|substance[72]	new[70]|new[71]|giv[72]	_	_
11-9	1581-1585	such	abstract[70]|abstract[71]|substance[72]	new[70]|new[71]|giv[72]	_	_
11-10	1586-1588	as	abstract[70]|abstract[71]|substance[72]	new[70]|new[71]|giv[72]	_	_
11-11	1589-1591	pH	abstract[70]|abstract[71]|substance[72]|abstract	new[70]|new[71]|giv[72]|new	coref	12-4
11-12	1592-1595	may	_	_	_	_
11-13	1596-1600	lead	_	_	_	_
11-14	1601-1603	to	_	_	_	_
11-15	1604-1611	changes	abstract[74]	new[74]	coref	12-21[85_74]
11-16	1612-1614	in	abstract[74]	new[74]	_	_
11-17	1615-1619	drug	abstract[74]|substance|abstract[76]	new[74]|giv|new[76]	coref	11-27[78_0]
11-18	1620-1630	solubility	abstract[74]|abstract[76]	new[74]|new[76]	_	_
11-19	1631-1634	and	_	_	_	_
11-20	1635-1636	,	_	_	_	_
11-21	1637-1646	therefore	_	_	_	_
11-22	1647-1648	,	_	_	_	_
11-23	1649-1651	in	_	_	_	_
11-24	1652-1662	absorption	event	new	_	_
11-25	1663-1668	since	_	_	_	_
11-26	1669-1673	only	_	_	_	_
11-27	1674-1677	the	substance[78]	giv[78]	coref	12-14[84_78]
11-28	1678-1687	dissolved	substance[78]	giv[78]	_	_
11-29	1688-1692	drug	substance[78]	giv[78]	_	_
11-30	1693-1698	would	_	_	_	_
11-31	1699-1701	be	_	_	_	_
11-32	1702-1711	available	_	_	_	_
11-33	1712-1715	for	_	_	_	_
11-34	1716-1726	absorption	event	new	coref	12-23[86_0]
11-35	1727-1728	.	_	_	_	_

#Text=Since fluctuations in pH may influence ionizable drugs and the relative amount of unionized available drug , there could be changes in absorption during maturation .
12-1	1729-1734	Since	_	_	_	_
12-2	1735-1747	fluctuations	abstract[80]	new[80]	_	_
12-3	1748-1750	in	abstract[80]	new[80]	_	_
12-4	1751-1753	pH	abstract[80]|abstract	new[80]|giv	coref	13-1[88_0]
12-5	1754-1757	may	_	_	_	_
12-6	1758-1767	influence	_	_	_	_
12-7	1768-1777	ionizable	substance[82]	giv[82]	coref	20-1[145_82]
12-8	1778-1783	drugs	substance[82]	giv[82]	_	_
12-9	1784-1787	and	substance[82]	giv[82]	_	_
12-10	1788-1791	the	substance[82]|quantity[83]	giv[82]|new[83]	_	_
12-11	1792-1800	relative	substance[82]|quantity[83]	giv[82]|new[83]	_	_
12-12	1801-1807	amount	substance[82]|quantity[83]	giv[82]|new[83]	_	_
12-13	1808-1810	of	substance[82]|quantity[83]	giv[82]|new[83]	_	_
12-14	1811-1820	unionized	substance[82]|quantity[83]|substance[84]	giv[82]|new[83]|giv[84]	coref	15-17[0_84]
12-15	1821-1830	available	substance[82]|quantity[83]|substance[84]	giv[82]|new[83]|giv[84]	_	_
12-16	1831-1835	drug	substance[82]|quantity[83]|substance[84]	giv[82]|new[83]|giv[84]	_	_
12-17	1836-1837	,	_	_	_	_
12-18	1838-1843	there	_	_	_	_
12-19	1844-1849	could	_	_	_	_
12-20	1850-1852	be	_	_	_	_
12-21	1853-1860	changes	abstract[85]	giv[85]	_	_
12-22	1861-1863	in	abstract[85]	giv[85]	_	_
12-23	1864-1874	absorption	abstract[85]|event[86]	giv[85]|giv[86]	_	_
12-24	1875-1881	during	abstract[85]|event[86]	giv[85]|giv[86]	_	_
12-25	1882-1892	maturation	abstract[85]|event[86]|event	giv[85]|giv[86]|new	_	_
12-26	1893-1894	.	_	_	_	_

#Text=The gastric pH of the newborn is approximately neutral , and within the first 48 h of life , the gastrointestinal pH decreases to adult values and then for the first month increases back to values close to neutrality .
13-1	1895-1898	The	abstract[88]	giv[88]	coref	13-20[92_88]
13-2	1899-1906	gastric	abstract[88]	giv[88]	_	_
13-3	1907-1909	pH	abstract[88]	giv[88]	_	_
13-4	1910-1912	of	abstract[88]	giv[88]	_	_
13-5	1913-1916	the	abstract[88]|person[89]	giv[88]|new[89]	_	_
13-6	1917-1924	newborn	abstract[88]|person[89]	giv[88]|new[89]	_	_
13-7	1925-1927	is	_	_	_	_
13-8	1928-1941	approximately	_	_	_	_
13-9	1942-1949	neutral	_	_	_	_
13-10	1950-1951	,	_	_	_	_
13-11	1952-1955	and	_	_	_	_
13-12	1956-1962	within	_	_	_	_
13-13	1963-1966	the	time[90]	new[90]	_	_
13-14	1967-1972	first	time[90]	new[90]	_	_
13-15	1973-1975	48	time[90]	new[90]	_	_
13-16	1976-1977	h	time[90]	new[90]	_	_
13-17	1978-1980	of	time[90]	new[90]	_	_
13-18	1981-1985	life	time[90]|time	new[90]|new	coref	19-22
13-19	1986-1987	,	_	_	_	_
13-20	1988-1991	the	abstract[92]	giv[92]	coref	14-6[100_92]
13-21	1992-2008	gastrointestinal	abstract[92]	giv[92]	_	_
13-22	2009-2011	pH	abstract[92]	giv[92]	_	_
13-23	2012-2021	decreases	_	_	_	_
13-24	2022-2024	to	_	_	_	_
13-25	2025-2030	adult	abstract[93]	new[93]	coref	13-36[96_93]
13-26	2031-2037	values	abstract[93]	new[93]	_	_
13-27	2038-2041	and	_	_	_	_
13-28	2042-2046	then	_	_	_	_
13-29	2047-2050	for	_	_	_	_
13-30	2051-2054	the	event[95]	new[95]	_	_
13-31	2055-2060	first	event[95]	new[95]	_	_
13-32	2061-2066	month	time|event[95]	new|new[95]	_	_
13-33	2067-2076	increases	event[95]	new[95]	_	_
13-34	2077-2081	back	event[95]	new[95]	_	_
13-35	2082-2084	to	event[95]	new[95]	_	_
13-36	2085-2091	values	event[95]|abstract[96]	new[95]|giv[96]	coref	14-12[101_96]
13-37	2092-2097	close	event[95]|abstract[96]	new[95]|giv[96]	_	_
13-38	2098-2100	to	_	_	_	_
13-39	2101-2111	neutrality	abstract	new	_	_
13-40	2112-2113	.	_	_	_	_

#Text=After the first month , gastric pH decreases progressively to reach similar values as in adults by two years of age .
14-1	2114-2119	After	_	_	_	_
14-2	2120-2123	the	time[98]	new[98]	_	_
14-3	2124-2129	first	time[98]	new[98]	_	_
14-4	2130-2135	month	time[98]	new[98]	_	_
14-5	2136-2137	,	_	_	_	_
14-6	2138-2145	gastric	abstract|abstract[100]	new|giv[100]	_	_
14-7	2146-2148	pH	abstract[100]	giv[100]	_	_
14-8	2149-2158	decreases	_	_	_	_
14-9	2159-2172	progressively	_	_	_	_
14-10	2173-2175	to	_	_	_	_
14-11	2176-2181	reach	_	_	_	_
14-12	2182-2189	similar	abstract[101]	giv[101]	_	_
14-13	2190-2196	values	abstract[101]	giv[101]	_	_
14-14	2197-2199	as	_	_	_	_
14-15	2200-2202	in	_	_	_	_
14-16	2203-2209	adults	person[102]	giv[102]	coref	19-24[0_102]
14-17	2210-2212	by	person[102]	giv[102]	_	_
14-18	2213-2216	two	person[102]|time[103]	giv[102]|new[103]	coref	17-20[128_103]
14-19	2217-2222	years	person[102]|time[103]	giv[102]|new[103]	_	_
14-20	2223-2225	of	person[102]|time[103]	giv[102]|new[103]	_	_
14-21	2226-2229	age	person[102]|time[103]|abstract	giv[102]|new[103]|new	coref	16-12
14-22	2230-2231	.	_	_	_	_

#Text=On the other hand , another determinant of bioavailability is ontogenic changes in the expression of drug metabolizing enzymes and transporters , which would mark the first pass effect and consequently would change the oral absorbed fraction .
15-1	2232-2234	On	_	_	_	_
15-2	2235-2238	the	_	_	_	_
15-3	2239-2244	other	_	_	_	_
15-4	2245-2249	hand	_	_	_	_
15-5	2250-2251	,	_	_	_	_
15-6	2252-2259	another	abstract[105]	new[105]	coref	15-11[107_105]
15-7	2260-2271	determinant	abstract[105]	new[105]	_	_
15-8	2272-2274	of	abstract[105]	new[105]	_	_
15-9	2275-2290	bioavailability	abstract[105]|abstract	new[105]|giv	_	_
15-10	2291-2293	is	_	_	_	_
15-11	2294-2303	ontogenic	abstract[107]	giv[107]	_	_
15-12	2304-2311	changes	abstract[107]	giv[107]	_	_
15-13	2312-2314	in	abstract[107]	giv[107]	_	_
15-14	2315-2318	the	abstract[107]|abstract[108]	giv[107]|new[108]	coref	16-8[0_108]
15-15	2319-2329	expression	abstract[107]|abstract[108]	giv[107]|new[108]	_	_
15-16	2330-2332	of	abstract[107]|abstract[108]	giv[107]|new[108]	_	_
15-17	2333-2337	drug	abstract[107]|abstract[108]|substance|substance[111]|abstract[112]	giv[107]|new[108]|giv|giv[111]|giv[112]	coref	18-17[135_111]
15-18	2338-2350	metabolizing	abstract[107]|abstract[108]|abstract|substance[111]|abstract[112]	giv[107]|new[108]|giv|giv[111]|giv[112]	_	_
15-19	2351-2358	enzymes	abstract[107]|abstract[108]|substance[111]|abstract[112]	giv[107]|new[108]|giv[111]|giv[112]	_	_
15-20	2359-2362	and	abstract[107]|abstract[108]|abstract[112]	giv[107]|new[108]|giv[112]	_	_
15-21	2363-2375	transporters	abstract[107]|abstract[108]|abstract[112]|person	giv[107]|new[108]|giv[112]|giv	_	_
15-22	2376-2377	,	_	_	_	_
15-23	2378-2383	which	_	_	_	_
15-24	2384-2389	would	_	_	_	_
15-25	2390-2394	mark	_	_	_	_
15-26	2395-2398	the	abstract[115]	new[115]	coref	26-56[201_115]
15-27	2399-2404	first	abstract[115]	new[115]	_	_
15-28	2405-2409	pass	abstract|abstract[115]	new|new[115]	_	_
15-29	2410-2416	effect	abstract[115]	new[115]	_	_
15-30	2417-2420	and	_	_	_	_
15-31	2421-2433	consequently	_	_	_	_
15-32	2434-2439	would	_	_	_	_
15-33	2440-2446	change	_	_	_	_
15-34	2447-2450	the	abstract[116]	new[116]	_	_
15-35	2451-2455	oral	abstract[116]	new[116]	_	_
15-36	2456-2464	absorbed	abstract[116]	new[116]	_	_
15-37	2465-2473	fraction	abstract[116]	new[116]	_	_
15-38	2474-2475	.	_	_	_	_

#Text=For example , the CYP3A4 isoenzyme increases expression and activity with age .
16-1	2476-2479	For	_	_	_	_
16-2	2480-2487	example	_	_	_	_
16-3	2488-2489	,	_	_	_	_
16-4	2490-2493	the	abstract[118]	new[118]	_	_
16-5	2494-2500	CYP3A4	abstract|abstract[118]	new|new[118]	coref	17-1
16-6	2501-2510	isoenzyme	abstract[118]	new[118]	_	_
16-7	2511-2520	increases	_	_	_	_
16-8	2521-2531	expression	abstract	giv	coref	17-9[125_0]
16-9	2532-2535	and	_	_	_	_
16-10	2536-2544	activity	abstract	giv	coref	18-10[132_0]
16-11	2545-2549	with	_	_	_	_
16-12	2550-2553	age	abstract	giv	coref	17-13
16-13	2554-2555	.	_	_	_	_

#Text=CYP3A4 is practically undetectable in neonates , and its expression increases with age , reaching a maximum level at two years of age .
17-1	2556-2562	CYP3A4	abstract	giv	ana	17-9
17-2	2563-2565	is	_	_	_	_
17-3	2566-2577	practically	_	_	_	_
17-4	2578-2590	undetectable	_	_	_	_
17-5	2591-2593	in	_	_	_	_
17-6	2594-2602	neonates	abstract	giv	_	_
17-7	2603-2604	,	_	_	_	_
17-8	2605-2608	and	_	_	_	_
17-9	2609-2612	its	abstract|abstract[125]	giv|giv[125]	coref	19-8[139_125]
17-10	2613-2623	expression	abstract[125]	giv[125]	_	_
17-11	2624-2633	increases	_	_	_	_
17-12	2634-2638	with	_	_	_	_
17-13	2639-2642	age	abstract	giv	coref	17-23
17-14	2643-2644	,	_	_	_	_
17-15	2645-2653	reaching	_	_	_	_
17-16	2654-2655	a	abstract[127]	new[127]	_	_
17-17	2656-2663	maximum	abstract[127]	new[127]	_	_
17-18	2664-2669	level	abstract[127]	new[127]	_	_
17-19	2670-2672	at	_	_	_	_
17-20	2673-2676	two	time[128]	giv[128]	_	_
17-21	2677-2682	years	time[128]	giv[128]	_	_
17-22	2683-2685	of	time[128]	giv[128]	_	_
17-23	2686-2689	age	time[128]|abstract	giv[128]|giv	coref	18-5
17-24	2690-2691	.	_	_	_	_

#Text=Likewise , in these age groups , there is immature intestinal activity of alkaline phosphatase , glucuronidation enzymes and carboxylesterase-2 .
18-1	2692-2700	Likewise	_	_	_	_
18-2	2701-2702	,	_	_	_	_
18-3	2703-2705	in	_	_	_	_
18-4	2706-2711	these	person[131]	new[131]	coref	25-36[178_131]
18-5	2712-2715	age	abstract|person[131]	giv|new[131]	coref	25-21
18-6	2716-2722	groups	person[131]	new[131]	_	_
18-7	2723-2724	,	_	_	_	_
18-8	2725-2730	there	_	_	_	_
18-9	2731-2733	is	_	_	_	_
18-10	2734-2742	immature	abstract[132]	giv[132]	_	_
18-11	2743-2753	intestinal	abstract[132]	giv[132]	_	_
18-12	2754-2762	activity	abstract[132]	giv[132]	_	_
18-13	2763-2765	of	abstract[132]	giv[132]	_	_
18-14	2766-2774	alkaline	abstract[132]|substance[133]	giv[132]|new[133]	_	_
18-15	2775-2786	phosphatase	abstract[132]|substance[133]	giv[132]|new[133]	_	_
18-16	2787-2788	,	abstract[132]	giv[132]	_	_
18-17	2789-2804	glucuronidation	abstract[132]|abstract|substance[135]	giv[132]|new|giv[135]	_	_
18-18	2805-2812	enzymes	abstract[132]|substance[135]	giv[132]|giv[135]	_	_
18-19	2813-2816	and	abstract[132]	giv[132]	_	_
18-20	2817-2835	carboxylesterase-2	abstract[132]|substance	giv[132]|new	_	_
18-21	2836-2837	.	_	_	_	_

#Text=Conversely , there are no differences in p-glycoprotein expression , the most studied intestinal efflux transporter from the earliest stages of life to adults .
19-1	2838-2848	Conversely	_	_	_	_
19-2	2849-2850	,	_	_	_	_
19-3	2851-2856	there	_	_	_	_
19-4	2857-2860	are	_	_	_	_
19-5	2861-2863	no	abstract[137]	giv[137]	_	_
19-6	2864-2875	differences	abstract[137]	giv[137]	_	_
19-7	2876-2878	in	abstract[137]	giv[137]	_	_
19-8	2879-2893	p-glycoprotein	abstract[137]|person|abstract[139]	giv[137]|new|giv[139]	_	_
19-9	2894-2904	expression	abstract[137]|abstract[139]	giv[137]|giv[139]	_	_
19-10	2905-2906	,	abstract[137]	giv[137]	_	_
19-11	2907-2910	the	abstract[137]|abstract[141]	giv[137]|new[141]	_	_
19-12	2911-2915	most	abstract[137]|abstract[141]	giv[137]|new[141]	_	_
19-13	2916-2923	studied	abstract[137]|abstract[141]	giv[137]|new[141]	_	_
19-14	2924-2934	intestinal	abstract[137]|abstract[141]	giv[137]|new[141]	_	_
19-15	2935-2941	efflux	abstract[137]|abstract|abstract[141]	giv[137]|giv|new[141]	_	_
19-16	2942-2953	transporter	abstract[137]|abstract[141]	giv[137]|new[141]	_	_
19-17	2954-2958	from	abstract[137]|abstract[141]	giv[137]|new[141]	_	_
19-18	2959-2962	the	abstract[137]|abstract[141]|abstract[142]	giv[137]|new[141]|new[142]	_	_
19-19	2963-2971	earliest	abstract[137]|abstract[141]|abstract[142]	giv[137]|new[141]|new[142]	_	_
19-20	2972-2978	stages	abstract[137]|abstract[141]|abstract[142]	giv[137]|new[141]|new[142]	_	_
19-21	2979-2981	of	abstract[137]|abstract[141]|abstract[142]	giv[137]|new[141]|new[142]	_	_
19-22	2982-2986	life	abstract[137]|abstract[141]|abstract[142]|abstract	giv[137]|new[141]|new[142]|giv	_	_
19-23	2987-2989	to	abstract[137]|abstract[141]|abstract[142]	giv[137]|new[141]|new[142]	_	_
19-24	2990-2996	adults	abstract[137]|abstract[141]|abstract[142]|person	giv[137]|new[141]|new[142]|giv	coref	21-8
19-25	2997-2998	.	_	_	_	_

#Text=Many drugs are formulated as pharmaceutical forms that are often not appropriate for pediatrics , such as tablets or capsules .
20-1	2999-3003	Many	substance[145]	giv[145]	_	_
20-2	3004-3009	drugs	substance[145]	giv[145]	_	_
20-3	3010-3013	are	_	_	_	_
20-4	3014-3024	formulated	_	_	_	_
20-5	3025-3027	as	_	_	_	_
20-6	3028-3042	pharmaceutical	_	_	_	_
20-7	3043-3048	forms	_	_	_	_
20-8	3049-3053	that	_	_	_	_
20-9	3054-3057	are	_	_	_	_
20-10	3058-3063	often	_	_	_	_
20-11	3064-3067	not	_	_	_	_
20-12	3068-3079	appropriate	_	_	_	_
20-13	3080-3083	for	_	_	_	_
20-14	3084-3094	pediatrics	abstract[146]	giv[146]	coref	22-1[159_146]
20-15	3095-3096	,	abstract[146]	giv[146]	_	_
20-16	3097-3101	such	abstract[146]	giv[146]	_	_
20-17	3102-3104	as	abstract[146]	giv[146]	_	_
20-18	3105-3112	tablets	abstract[146]|object	giv[146]|new	_	_
20-19	3113-3115	or	abstract[146]	giv[146]	_	_
20-20	3116-3124	capsules	abstract[146]|object	giv[146]|new	_	_
20-21	3125-3126	.	_	_	_	_

#Text=Children need different oral dosage formulations from adults mainly due to their developmental capabilities in swallowing ability , palatability and dosage requirements .
21-1	3127-3135	Children	person	giv	coref	26-59
21-2	3136-3140	need	_	_	_	_
21-3	3141-3150	different	abstract[151]	new[151]	coref	24-13[169_151]
21-4	3151-3155	oral	abstract[151]	new[151]	_	_
21-5	3156-3162	dosage	substance|abstract[151]	new|new[151]	coref	21-21
21-6	3163-3175	formulations	abstract[151]	new[151]	_	_
21-7	3176-3180	from	abstract[151]	new[151]	_	_
21-8	3181-3187	adults	abstract[151]|person	new[151]|giv	ana	21-12
21-9	3188-3194	mainly	_	_	_	_
21-10	3195-3198	due	_	_	_	_
21-11	3199-3201	to	_	_	_	_
21-12	3202-3207	their	person|abstract[154]	giv|new[154]	_	_
21-13	3208-3221	developmental	abstract[154]	new[154]	_	_
21-14	3222-3234	capabilities	abstract[154]	new[154]	_	_
21-15	3235-3237	in	_	_	_	_
21-16	3238-3248	swallowing	_	_	_	_
21-17	3249-3256	ability	abstract	new	_	_
21-18	3257-3258	,	_	_	_	_
21-19	3259-3271	palatability	abstract	new	coref	22-5
21-20	3272-3275	and	_	_	_	_
21-21	3276-3282	dosage	quantity|abstract[158]	giv|new[158]	_	_
21-22	3283-3295	requirements	abstract[158]	new[158]	_	_
21-23	3296-3297	.	_	_	_	_

#Text=Especially in pediatrics , palatability is closely related to acceptance and adherence .
22-1	3298-3308	Especially	abstract[159]	giv[159]	coref	24-8[0_159]
22-2	3309-3311	in	abstract[159]	giv[159]	_	_
22-3	3312-3322	pediatrics	abstract[159]	giv[159]	_	_
22-4	3323-3324	,	_	_	_	_
22-5	3325-3337	palatability	abstract	giv	_	_
22-6	3338-3340	is	_	_	_	_
22-7	3341-3348	closely	_	_	_	_
22-8	3349-3356	related	_	_	_	_
22-9	3357-3359	to	_	_	_	_
22-10	3360-3370	acceptance	abstract	new	_	_
22-11	3371-3374	and	_	_	_	_
22-12	3375-3384	adherence	abstract	new	_	_
22-13	3385-3386	.	_	_	_	_

#Text=Consequently , bitterness , trigeminal irritation and perceptible malodors must be minimized .
23-1	3387-3399	Consequently	_	_	_	_
23-2	3400-3401	,	_	_	_	_
23-3	3402-3412	bitterness	abstract	new	_	_
23-4	3413-3414	,	_	_	_	_
23-5	3415-3425	trigeminal	abstract[164]	new[164]	_	_
23-6	3426-3436	irritation	abstract[164]	new[164]	_	_
23-7	3437-3440	and	_	_	_	_
23-8	3441-3452	perceptible	abstract[165]	new[165]	_	_
23-9	3453-3461	malodors	abstract[165]	new[165]	_	_
23-10	3462-3466	must	_	_	_	_
23-11	3467-3469	be	_	_	_	_
23-12	3470-3479	minimized	_	_	_	_
23-13	3480-3481	.	_	_	_	_

#Text=The increasing need for age-related medicines in pediatrics could be met by extemporaneous formulations .
24-1	3482-3485	The	abstract[166]	giv[166]	coref	25-57[181_166]
24-2	3486-3496	increasing	abstract[166]	giv[166]	_	_
24-3	3497-3501	need	abstract[166]	giv[166]	_	_
24-4	3502-3505	for	abstract[166]	giv[166]	_	_
24-5	3506-3517	age-related	abstract[166]|substance[167]	giv[166]|giv[167]	coref	27-25[209_167]
24-6	3518-3527	medicines	abstract[166]|substance[167]	giv[166]|giv[167]	_	_
24-7	3528-3530	in	abstract[166]|substance[167]	giv[166]|giv[167]	_	_
24-8	3531-3541	pediatrics	abstract[166]|substance[167]|abstract	giv[166]|giv[167]|giv	coref	27-37
24-9	3542-3547	could	_	_	_	_
24-10	3548-3550	be	_	_	_	_
24-11	3551-3554	met	_	_	_	_
24-12	3555-3557	by	_	_	_	_
24-13	3558-3572	extemporaneous	abstract[169]	giv[169]	coref	26-8[185_169]
24-14	3573-3585	formulations	abstract[169]	giv[169]	_	_
24-15	3586-3587	.	_	_	_	_

#Text=The compounding of an extemporaneous formula is not allowed if an authorized commercial pharmaceutical product ( adequate for a particular age group ) exists , but the reality in the clinical setting is that for some age groups , that is not the case , while extemporaneous formulation is still used as the only alternative to the therapeutic need .
25-1	3588-3591	The	event[170]	new[170]	_	_
25-2	3592-3603	compounding	event[170]	new[170]	_	_
25-3	3604-3606	of	event[170]	new[170]	_	_
25-4	3607-3609	an	event[170]|object[171]	new[170]|new[171]	_	_
25-5	3610-3624	extemporaneous	event[170]|object[171]	new[170]|new[171]	_	_
25-6	3625-3632	formula	event[170]|object[171]	new[170]|new[171]	_	_
25-7	3633-3635	is	_	_	_	_
25-8	3636-3639	not	_	_	_	_
25-9	3640-3647	allowed	_	_	_	_
25-10	3648-3650	if	_	_	_	_
25-11	3651-3653	an	object[172]	new[172]	_	_
25-12	3654-3664	authorized	object[172]	new[172]	_	_
25-13	3665-3675	commercial	object[172]	new[172]	_	_
25-14	3676-3690	pharmaceutical	object[172]	new[172]	_	_
25-15	3691-3698	product	object[172]	new[172]	_	_
25-16	3699-3700	(	_	_	_	_
25-17	3701-3709	adequate	_	_	_	_
25-18	3710-3713	for	_	_	_	_
25-19	3714-3715	a	abstract[174]	new[174]	coref	27-13[207_174]
25-20	3716-3726	particular	abstract[174]	new[174]	_	_
25-21	3727-3730	age	abstract|abstract[174]	giv|new[174]	coref	25-37
25-22	3731-3736	group	abstract[174]	new[174]	_	_
25-23	3737-3738	)	_	_	_	_
25-24	3739-3745	exists	_	_	_	_
25-25	3746-3747	,	_	_	_	_
25-26	3748-3751	but	_	_	_	_
25-27	3752-3755	the	abstract[175]	new[175]	_	_
25-28	3756-3763	reality	abstract[175]	new[175]	_	_
25-29	3764-3766	in	abstract[175]	new[175]	_	_
25-30	3767-3770	the	abstract[175]|abstract[176]	new[175]|new[176]	ana	25-40[0_176]
25-31	3771-3779	clinical	abstract[175]|abstract[176]	new[175]|new[176]	_	_
25-32	3780-3787	setting	abstract[175]|abstract[176]	new[175]|new[176]	_	_
25-33	3788-3790	is	_	_	_	_
25-34	3791-3795	that	_	_	_	_
25-35	3796-3799	for	_	_	_	_
25-36	3800-3804	some	person[178]	giv[178]	_	_
25-37	3805-3808	age	abstract|person[178]	giv|giv[178]	coref	27-14
25-38	3809-3815	groups	person[178]	giv[178]	_	_
25-39	3816-3817	,	_	_	_	_
25-40	3818-3822	that	abstract	giv	_	_
25-41	3823-3825	is	_	_	_	_
25-42	3826-3829	not	_	_	_	_
25-43	3830-3833	the	_	_	_	_
25-44	3834-3838	case	_	_	_	_
25-45	3839-3840	,	_	_	_	_
25-46	3841-3846	while	_	_	_	_
25-47	3847-3861	extemporaneous	abstract[180]	giv[180]	_	_
25-48	3862-3873	formulation	abstract[180]	giv[180]	_	_
25-49	3874-3876	is	_	_	_	_
25-50	3877-3882	still	_	_	_	_
25-51	3883-3887	used	_	_	_	_
25-52	3888-3890	as	_	_	_	_
25-53	3891-3894	the	_	_	_	_
25-54	3895-3899	only	_	_	_	_
25-55	3900-3911	alternative	_	_	_	_
25-56	3912-3914	to	_	_	_	_
25-57	3915-3918	the	abstract[181]	giv[181]	_	_
25-58	3919-3930	therapeutic	abstract[181]	giv[181]	_	_
25-59	3931-3935	need	abstract[181]	giv[181]	_	_
25-60	3936-3937	.	_	_	_	_

#Text=Although solid products have higher stability than liquid formulations , this practice can solve the problem of swallowing capability and dose adjustments , but these manufactured preparations can be a risk to safety , efficacy and quality , because there is little or no information for compatibility between the original medicine and additional excipients or their effect in children .
26-1	3938-3946	Although	_	_	_	_
26-2	3947-3952	solid	object[182]	new[182]	_	_
26-3	3953-3961	products	object[182]	new[182]	_	_
26-4	3962-3966	have	_	_	_	_
26-5	3967-3973	higher	abstract[183]	new[183]	_	_
26-6	3974-3983	stability	abstract[183]	new[183]	_	_
26-7	3984-3988	than	abstract[183]	new[183]	_	_
26-8	3989-3995	liquid	abstract[183]|substance|abstract[185]	new[183]|new|giv[185]	coref	27-5[0_185]
26-9	3996-4008	formulations	abstract[183]|abstract[185]	new[183]|giv[185]	_	_
26-10	4009-4010	,	_	_	_	_
26-11	4011-4015	this	event[186]	new[186]	_	_
26-12	4016-4024	practice	event[186]	new[186]	_	_
26-13	4025-4028	can	_	_	_	_
26-14	4029-4034	solve	_	_	_	_
26-15	4035-4038	the	abstract[187]	new[187]	_	_
26-16	4039-4046	problem	abstract[187]	new[187]	_	_
26-17	4047-4049	of	abstract[187]	new[187]	_	_
26-18	4050-4060	swallowing	abstract[187]|abstract[188]	new[187]|new[188]	_	_
26-19	4061-4071	capability	abstract[187]|abstract[188]	new[187]|new[188]	_	_
26-20	4072-4075	and	abstract[187]	new[187]	_	_
26-21	4076-4080	dose	abstract[187]|quantity|abstract[190]	new[187]|new|new[190]	_	_
26-22	4081-4092	adjustments	abstract[187]|abstract[190]	new[187]|new[190]	_	_
26-23	4093-4094	,	_	_	_	_
26-24	4095-4098	but	_	_	_	_
26-25	4099-4104	these	abstract[191]	new[191]	coref	26-30[192_191]
26-26	4105-4117	manufactured	abstract[191]	new[191]	_	_
26-27	4118-4130	preparations	abstract[191]	new[191]	_	_
26-28	4131-4134	can	_	_	_	_
26-29	4135-4137	be	_	_	_	_
26-30	4138-4139	a	abstract[192]	giv[192]	_	_
26-31	4140-4144	risk	abstract[192]	giv[192]	_	_
26-32	4145-4147	to	abstract[192]	giv[192]	_	_
26-33	4148-4154	safety	abstract[192]|abstract	giv[192]|new	_	_
26-34	4155-4156	,	abstract[192]	giv[192]	_	_
26-35	4157-4165	efficacy	abstract[192]|abstract	giv[192]|new	_	_
26-36	4166-4169	and	abstract[192]	giv[192]	_	_
26-37	4170-4177	quality	abstract[192]|abstract	giv[192]|new	_	_
26-38	4178-4179	,	_	_	_	_
26-39	4180-4187	because	_	_	_	_
26-40	4188-4193	there	_	_	_	_
26-41	4194-4196	is	_	_	_	_
26-42	4197-4203	little	_	_	_	_
26-43	4204-4206	or	_	_	_	_
26-44	4207-4209	no	abstract[196]	new[196]	_	_
26-45	4210-4221	information	abstract[196]	new[196]	_	_
26-46	4222-4225	for	abstract[196]	new[196]	_	_
26-47	4226-4239	compatibility	abstract[196]|abstract[197]	new[196]|new[197]	_	_
26-48	4240-4247	between	abstract[196]|abstract[197]	new[196]|new[197]	_	_
26-49	4248-4251	the	abstract[196]|abstract[197]|substance[198]|abstract[199]	new[196]|new[197]|new[198]|new[199]	_	_
26-50	4252-4260	original	abstract[196]|abstract[197]|substance[198]|abstract[199]	new[196]|new[197]|new[198]|new[199]	_	_
26-51	4261-4269	medicine	abstract[196]|abstract[197]|substance[198]|abstract[199]	new[196]|new[197]|new[198]|new[199]	_	_
26-52	4270-4273	and	abstract[196]|abstract[197]|abstract[199]	new[196]|new[197]|new[199]	_	_
26-53	4274-4284	additional	abstract[196]|abstract[197]|abstract[199]|object[200]	new[196]|new[197]|new[199]|new[200]	coref	27-1[203_200]
26-54	4285-4295	excipients	abstract[196]|abstract[197]|abstract[199]|object[200]	new[196]|new[197]|new[199]|new[200]	_	_
26-55	4296-4298	or	abstract[196]|abstract[197]|abstract[199]	new[196]|new[197]|new[199]	_	_
26-56	4299-4304	their	abstract[196]|abstract[197]|abstract[199]|abstract[201]	new[196]|new[197]|new[199]|giv[201]	_	_
26-57	4305-4311	effect	abstract[196]|abstract[197]|abstract[199]|abstract[201]	new[196]|new[197]|new[199]|giv[201]	_	_
26-58	4312-4314	in	abstract[196]|abstract[197]|abstract[199]|abstract[201]	new[196]|new[197]|new[199]|giv[201]	_	_
26-59	4315-4323	children	abstract[196]|abstract[197]|abstract[199]|abstract[201]|person	new[196]|new[197]|new[199]|giv[201]|giv	coref	27-8
26-60	4324-4325	.	_	_	_	_

#Text=The excipients used in formulations designed for children should be appropriate for each age group because , as is known , these are not inert substances and cannot be supposed to have the same effects in pediatrics as in adults .
27-1	4326-4329	The	object[203]	giv[203]	coref	29-15[220_203]
27-2	4330-4340	excipients	object[203]	giv[203]	_	_
27-3	4341-4345	used	_	_	_	_
27-4	4346-4348	in	_	_	_	_
27-5	4349-4361	formulations	abstract	giv	coref	29-8[218_0]
27-6	4362-4370	designed	_	_	_	_
27-7	4371-4374	for	_	_	_	_
27-8	4375-4383	children	person	giv	ana	27-22
27-9	4384-4390	should	_	_	_	_
27-10	4391-4393	be	_	_	_	_
27-11	4394-4405	appropriate	_	_	_	_
27-12	4406-4409	for	_	_	_	_
27-13	4410-4414	each	abstract[207]	giv[207]	_	_
27-14	4415-4418	age	abstract|abstract[207]	giv|giv[207]	_	_
27-15	4419-4424	group	abstract[207]	giv[207]	_	_
27-16	4425-4432	because	_	_	_	_
27-17	4433-4434	,	_	_	_	_
27-18	4435-4437	as	_	_	_	_
27-19	4438-4440	is	_	_	_	_
27-20	4441-4446	known	_	_	_	_
27-21	4447-4448	,	_	_	_	_
27-22	4449-4454	these	person	giv	coref	28-6[214_0]
27-23	4455-4458	are	_	_	_	_
27-24	4459-4462	not	_	_	_	_
27-25	4463-4468	inert	substance[209]	giv[209]	_	_
27-26	4469-4479	substances	substance[209]	giv[209]	_	_
27-27	4480-4483	and	_	_	_	_
27-28	4484-4490	cannot	_	_	_	_
27-29	4491-4493	be	_	_	_	_
27-30	4494-4502	supposed	_	_	_	_
27-31	4503-4505	to	_	_	_	_
27-32	4506-4510	have	_	_	_	_
27-33	4511-4514	the	abstract[210]	new[210]	_	_
27-34	4515-4519	same	abstract[210]	new[210]	_	_
27-35	4520-4527	effects	abstract[210]	new[210]	_	_
27-36	4528-4530	in	abstract[210]	new[210]	_	_
27-37	4531-4541	pediatrics	abstract[210]|abstract	new[210]|giv	_	_
27-38	4542-4544	as	_	_	_	_
27-39	4545-4547	in	_	_	_	_
27-40	4548-4554	adults	_	_	_	_
27-41	4555-4556	.	_	_	_	_

#Text=The most common example is early stage children who are not able to metabolize or eliminate them as adults .
28-1	4557-4560	The	abstract[212]	new[212]	_	_
28-2	4561-4565	most	abstract[212]	new[212]	_	_
28-3	4566-4572	common	abstract[212]	new[212]	_	_
28-4	4573-4580	example	abstract[212]	new[212]	_	_
28-5	4581-4583	is	_	_	_	_
28-6	4584-4589	early	person[214]	giv[214]	ana	28-17[0_214]
28-7	4590-4595	stage	abstract|person[214]	new|giv[214]	_	_
28-8	4596-4604	children	person[214]	giv[214]	_	_
28-9	4605-4608	who	_	_	_	_
28-10	4609-4612	are	_	_	_	_
28-11	4613-4616	not	_	_	_	_
28-12	4617-4621	able	_	_	_	_
28-13	4622-4624	to	_	_	_	_
28-14	4625-4635	metabolize	_	_	_	_
28-15	4636-4638	or	_	_	_	_
28-16	4639-4648	eliminate	_	_	_	_
28-17	4649-4653	them	person	giv	_	_
28-18	4654-4656	as	_	_	_	_
28-19	4657-4663	adults	_	_	_	_
28-20	4664-4665	.	_	_	_	_

#Text=The ideal situation in the development of pediatric formulations is the minimal use of added excipients , both in number and quantity .
29-1	4666-4669	The	abstract[216]	new[216]	coref	29-11[219_216]
29-2	4670-4675	ideal	abstract[216]	new[216]	_	_
29-3	4676-4685	situation	abstract[216]	new[216]	_	_
29-4	4686-4688	in	abstract[216]	new[216]	_	_
29-5	4689-4692	the	abstract[216]|event[217]	new[216]|new[217]	_	_
29-6	4693-4704	development	abstract[216]|event[217]	new[216]|new[217]	_	_
29-7	4705-4707	of	abstract[216]|event[217]	new[216]|new[217]	_	_
29-8	4708-4717	pediatric	abstract[216]|event[217]|abstract[218]	new[216]|new[217]|giv[218]	_	_
29-9	4718-4730	formulations	abstract[216]|event[217]|abstract[218]	new[216]|new[217]|giv[218]	_	_
29-10	4731-4733	is	_	_	_	_
29-11	4734-4737	the	abstract[219]	giv[219]	_	_
29-12	4738-4745	minimal	abstract[219]	giv[219]	_	_
29-13	4746-4749	use	abstract[219]	giv[219]	_	_
29-14	4750-4752	of	abstract[219]	giv[219]	_	_
29-15	4753-4758	added	abstract[219]|object[220]	giv[219]|giv[220]	_	_
29-16	4759-4769	excipients	abstract[219]|object[220]	giv[219]|giv[220]	_	_
29-17	4770-4771	,	abstract[219]	giv[219]	_	_
29-18	4772-4776	both	abstract[219]	giv[219]	_	_
29-19	4777-4779	in	abstract[219]	giv[219]	_	_
29-20	4780-4786	number	abstract[219]|abstract	giv[219]|new	_	_
29-21	4787-4790	and	abstract[219]	giv[219]	_	_
29-22	4791-4799	quantity	abstract[219]|quantity	giv[219]|new	_	_
29-23	4800-4801	.	_	_	_	_
